Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narrow-spectrum versus broad-spectrum oral antibiotics for mild to moderate diabetic foot infection
ACTRN12619001190190Phase 4Recruiting
- Sponsor
- South West Sydney Limb Preservation and Wound Research
- Start
- Feb 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of flucloxacillin, dicloxacillin, clindamycin, amoxicillin + clavulanate and ciprofloxacin in diabetic foot infection (DFI) (2 arms), sponsored by South West Sydney Limb Preservation and Wound Research. Primary endpoint: Clinical cure of infection. Started Feb 2020; status: recruiting.
02
Drugs
flucloxacillindicloxacillinclindamycinamoxicillin + clavulanateciprofloxacin
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on ACTRN12619001190190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001190190.